

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshiaki Sai, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126 (Public Relations)

+81-3-6225-1125 (Investor Relations)

<http://www.daiichisankyo.com/>

**Daiichi Sankyo Announces First European Approval for Sevikar HCT<sup>®</sup>,**

**a New Three-in-one Combination Product for the Treatment of High Blood Pressure**

Attached is the co-press release with DAIICHI SANKYO EUROPE GmbH , a subsidiary of Daiichi Sankyo Co., Ltd. which was issued on December 20, 2010.



**Daiichi-Sankyo**

PRESS RELEASE  
20 December 2010, 10:00 CET

DAIICHI SANKYO EUROPE GmbH  
Zielstattstrasse 48  
81379 Munich · Germany  
Phone +49(0)89/78 08-685  
Fax +49(0)89/78 08-701  
[www.daiichi-sankyo.eu](http://www.daiichi-sankyo.eu)

## **Daiichi Sankyo Announces First European Approval for Sevikar HCT<sup>®</sup>, a New Three-in-one Combination Product for the Treatment of High Blood Pressure\***

**New Treatment Option Contributes to Fight Against Hypertension, Which Affects over 30% of Adults in Europe<sup>1</sup>**

Munich, 20 December 2010 – Daiichi Sankyo Europe announced today that Sevikar HCT<sup>®</sup> is now approved in Germany, the first market to launch this new once-daily three-in-one combination product for the treatment of high blood pressure (BP). This new drug combines the three widely prescribed blood pressure treatments - olmesartan medoxomil, amlodipine, and hydrochlorothiazide (HCT) - in one single pill to help effectively control hypertension.<sup>2</sup>

The approval of Sevikar HCT<sup>®</sup> in Germany was granted after the European decentralised procedure was closed with a positive recommendation on the drug.

With the approval of Sevikar HCT<sup>®</sup>, Daiichi Sankyo offers physicians a comprehensive range of olmesartan based therapies to help them to successfully treat their patients to the accepted target blood pressure of less than 140/90 mmHg.

\*Sevikar HCT<sup>®</sup> is indicated as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide, taken as a dual-component (olmesartan medoxomil and amlodipine or olmesartan medoxomil and hydrochlorothiazide) and a single-component formulation (hydrochlorothiazide or amlodipine).<sup>3</sup>

SEV/10/0004  
Dec 2010

“The approval for Sevikar HCT<sup>®</sup> is good news for both patients and physicians in Europe,” said Reinhard Bauer, CEO of Daiichi Sankyo Europe, “With olmesartan as the foundation for this new treatment option, we are confident that Sevikar HCT<sup>®</sup> will provide doctors with an additional therapy option to successfully treat their patients to blood pressure targets.”

Evidence shows that up to two-thirds of hypertensive patients require multiple medications from different classes of treatment, and many need three or more to reach the accepted blood pressure goal of 140/90 mmHg.<sup>4,5,6</sup> The fixed-dose combination therapy Sevikar HCT<sup>®</sup> will provide doctors with a new treatment option to prescribe to patients, that simplifies treatment, provides patients with a more convenient option and decreases overall pill burden. Giving drugs as a single-pill fixed dose combination significantly improves compliance, and favors BP control compared with the same drugs given separately as two or more pills.<sup>7</sup>

The approval Sevikar HCT<sup>®</sup> completes the Daiichi Sankyo portfolio for the treatment of high blood pressure. The portfolio includes:

- Olmetec<sup>®</sup> (olmesartan medoxomil)
- Olmetec Plus<sup>®</sup> ▼ (olmesartan + hydrochlorothiazide)
- Sevikar<sup>®</sup> ▼ (olmesartan + amlodipine)
- Sevikar HCT<sup>®</sup> (olmesartan + amlodipine + hydrochlorothiazide)

### **About hypertension**

Hypertension is one of the most prevalent conditions in Europe affecting approximately one in three adults and approximately one billion people worldwide.<sup>8</sup> It is often challenging to control, and of those diagnosed with high blood pressure, approximately 65 percent do not have the condition under control.<sup>9</sup>

High blood pressure can cause permanent changes to blood vessels and the heart that may create serious problems elsewhere in the body. We know that tight BP control, as opposed to settling for treating patients to 5-10 mmHg above goal, can make a great deal of difference, reducing incidence of stroke by an impressive 44% and deaths by 32%.<sup>10</sup>

### **About Daiichi Sankyo**

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimise growth opportunities across the value chain. For more information, please visit: [www.daiichisankyo.com](http://www.daiichisankyo.com).

The company's world headquarters are in Tokyo. Its European base is located in Munich. DAIICHI SANKYO EUROPE has affiliates in 12 European countries in addition to a global manufacturing site located in Pfaffenhofen, Germany.

### **Legal disclaimer (Forward-looking statement)**

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO, Co. Ltd, DAIICHI SANKYO, Inc., and DAIICHI SANKYO EUROPE GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the

company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO, Co. Ltd, DAIICHI SANKYO, Inc., and DAIICHI SANKYO EUROPE GmbH assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

## References

- <sup>1</sup> Kearney PM, et al. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. *J Hypertens* 2004;22:11-19
- <sup>2</sup> Oparil S, Melino M, Lee J, Fernandez V and Heyrman R. Triple therapy with Olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. *Clin Ther* 2010; 32(7); 1252-1269
- <sup>3</sup> Fachinformation Sevika<sup>®</sup> HCT, Stand: Dezember 2010
- <sup>4</sup> National High Blood Pressure Education Program, JNC 7: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, December, 2003.
- <sup>5</sup> Cushman WC, et al. Success and predictors of blood pressure control in diverse North Am settings: the antihypertensive and lipid lowering treatment to prevent heart attack trial(ALLHAT). *J Clin Hypertens* (Greenwich). 2002;4:393– 404.
- <sup>6</sup> Hansson L, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet* 1998;351(9118):1755-62.
- <sup>7</sup> Mancia, G., et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *J Hypertens*;2009. 27: 2121-2158.
- <sup>8</sup> Gupta AK, Arshad S and Poulter NR. Compliance, safety, and effectiveness of fixed-dos combinations of antihypertensive agents: a meta-analysis. *Hypertension* 2010;55(2); 399-407
- <sup>9</sup> Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. *J Hypertens* 2004;22:11-19
- <sup>10</sup> Bakris, et al. Preserving renal function in Adults with Hypertension and Diabetes: A consensus approach. *Am J Kidney Dis*, 2000;36(3):646-661

## CONTACT

### Public Relations

**Dr. Michaela Paudler-Debus**

**Head of Product PR Europe**

**Phone +49 89 78 08 685**

**[michaela.paudler-debus@daiichi-sankyo.eu](mailto:michaela.paudler-debus@daiichi-sankyo.eu)**

### Medical

**Joris Verstedden**

**Vice Director Medical and Scientific Affairs**

**Phone +49 89 78 08 497**

**[joris.verstedden@daiichi-sankyo.eu](mailto:joris.verstedden@daiichi-sankyo.eu)**